The Science Based Targets Initiative (SBTi) has officially validated Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma’s core purpose of “Doing Well and Doing Good,” driving its business strategies and strengthening its commitment to making consistent, measurable progress toward a more sustainable future.
 
Piramal Pharma has committed to reducing absolute scope 1 and 2 GHG emissions by 42% by FY2030 from a FY2022 base year. The company has also committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and use of sold products by 25% within the same timeframe.
 
“Sustainability is at the heart of our business strategy, and the approval from SBTi reinforces our ongoing commitment to reducing our GHG emissions and aligning with global climate action goals,” said Nandini Piramal, Chairperson, Piramal Pharma Limited. “This is a critical step in our broader sustainability roadmap, and we are committed to doing our part in driving meaningful environmental change across the pharmaceutical industry. To further reinforce our commitment, we are also in the process of developing a comprehensive Carbon Reduction Plan, which will be unveiled soon. While we have come a long way, in many respects, our sustainability journey is just beginning.”